These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38909529)

  • 21. Clinical outcome predictors for metastatic renal cell carcinoma: a retrospective multicenter real-life case series.
    Rizzo M; Pezzicoli G; Tibollo V; Premoli A; Quaglini S
    BMC Cancer; 2024 Jul; 24(1):804. PubMed ID: 38970009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials.
    Massari F; Rizzo A; Mollica V; Rosellini M; Marchetti A; Ardizzoni A; Santoni M
    Eur J Cancer; 2021 Sep; 154():120-127. PubMed ID: 34265504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
    Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis.
    Yoshida K; Nagasaka N; Kondo T; Kobari Y; Ishihara H; Fukuda H; Iizuka J; Ishida H; Takagi T
    Int J Clin Oncol; 2024 Oct; 29(10):1538-1547. PubMed ID: 39110357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk.
    Kartolo A; Holstead RG; Duran I; Robinson AG; Vera-Badillo FE
    Urology; 2021 Nov; 157():8-14. PubMed ID: 34461142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features.
    Fontes-Sousa M; Calvo E
    Cancer Treat Rev; 2022 Apr; 105():102374. PubMed ID: 35303549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials.
    Tucci M; Mandarà M; Giuliani J; Durante E; Buttigliero C; Turco F; Palesandro E; Campisi I; Singh N; Muraro M; Munoz F; Fiorica F
    Cancer Treat Rev; 2024 Jun; 127():102745. PubMed ID: 38723394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy.
    Yanagisawa T; Kawada T; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Chlosta M; Quhal F; Pradere B; Karakiewicz PI; Mori K; Kimura T; Shariat SF; Schmidinger M
    BJU Int; 2024 Sep; 134(3):323-336. PubMed ID: 38659099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
    Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
    Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
    Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
    Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors.
    Xu X; Wang J; Wang Y; Zhu Y; Wang J; Guo J
    Cell Oncol (Dordr); 2024 Oct; 47(5):1943-1956. PubMed ID: 39222176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study).
    Rebuzzi SE; Fornarini G; Signori A; Buti S; Procopio G; De Giorgi U; Pignata S; Naglieri E; Maruzzo M; Banna GL; Rescigno P; Messina C; Mattana A; Basso U; Bimbatti D
    BMC Cancer; 2024 Jun; 24(1):757. PubMed ID: 38914928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
    Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study).
    Ciccarese C; Büttner T; Cerbone L; Zampiva I; Monteiro FSM; Basso U; Pichler M; Vitale MG; Fiala O; Roviello G; Kopp RM; Carrozza F; Pichler R; Grillone F; Calabuig EP; Zeppellini A; Küronya Z; Galli L; Facchini G; Sunela K; Mosca A; Molina-Cerrillo J; Spinelli GP; Ansari J; Scala A; Mollica V; Grande E; Buti S; Kanesvaran R; Zakopoulou R; Bamias A; Rizzo M; Massari F; Iacovelli R; Santoni M
    Int J Cancer; 2024 Dec; 155(11):2036-2046. PubMed ID: 39243397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
    Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
    Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines.
    Resch I; Bruchbacher A; Franke J; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    ESMO Open; 2021 Aug; 6(4):100122. PubMed ID: 34217917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
    Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
    Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.